UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Cardiovascular disease (CVD) markers in patients(pts) with prostate cancer(PCa) treated with GN-RH agonists(AG) or antagonist(AN): a prospective cohort study

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi21

2017

Volltextzugriff (PDF)

Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi22

2017

Volltextzugriff (PDF)

Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature

ESMO open, 2023-02, Vol.8 (1), p.100791-100791, Article 100791

2023

Volltextzugriff (PDF)

301 IRON OVERLOAD AND IRON CHELATION THERAPY WITH DEFERASIROX IN TRANSFUSION-DEPENDENT PATIENTS WITH MYELODYSPLASTIC SYNDROMES

Leukemia research, 2015-04, Vol.39, p.S150-S150

2015

Volltextzugriff (PDF)

202 BOTH AGE AND COMORBIDITIES NEGATIVELY IMPACT ON CLINICAL OUTCOME OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES: RESULTS FROM A REAL-LIFE REGIONAL SURVEY

Leukemia research, 2015-04, Vol.39, p.S100-S101

2015

Volltextzugriff (PDF)

P-158 Real-life current management of patients with myelodysplastic syndromes: A survey from a regional registry in north-western Italy

Leukemia research, 2013-05, Vol.37, p.S95-S95

2013

Volltextzugriff (PDF)

P-294 Azacytidine therapy for MDS and AML patients: Retrospective multicentre regional experience in patients not enrolled into clinical trials

Leukemia research, 2013-05, Vol.37, p.S155-S155

2013

Volltextzugriff (PDF)

P-140 Combined overexpression of WT1 and BAALC may predict evolution in MDS

Leukemia research, 2013-05, Vol.37, p.S86-S87

2013

Volltextzugriff (PDF)

1581P Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors (ICIs): Pooled analysis of individual cases from multiple institutions and literature

Annals of oncology, 2022-09, Vol.33, p.S1268

2022

Volltextzugriff (PDF)

379 Serum hepcidin in patients with myelodysplastic syndrome and primary myelofibrosis

Leukemia research, 2011, Vol.35, p.S151-S151

2011

Volltextzugriff (PDF)

Dexamethazone-induced Acute Tumor Lysis Syndrome in a T-cell Malignant Lymphoma

Leukemia & lymphoma, 2002, Vol.43 (5), p.1129-1132

2002

Volltextzugriff (PDF)

Effects of retinoic acid and amifostine on in vitro growth of normal hemopoietic progenitor cells

Anticancer research, 2001-03, Vol.21 (2A), p.1139

2001

Volltextzugriff (PDF)

Thalidomide-induced cardiotoxicity in multiple myeloma patients: An underestimated but clinically relevant issue

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e18544-e18544

2010

Volltextzugriff (PDF)

In vitro synergistic inhibition of human bone marrow hemopoietic progenitor growth by a 3'-azido-3'-deoxy-thymidine, 2',3'-dideoxycytidine combination

Experimental hematology, 1997-03, Vol.25 (3), p.252

1997

Volltextzugriff (PDF)

Amifostine promotes hemopoietic progenitor cell mobilization in patients with myelodysplastic syndrome

Anticancer research, 2002-05, Vol.22 (3), p.1819

2002

Volltextzugriff (PDF)

Epithelioid granulomas as main clinical manifestation at the outset of non-Hodgkin's lymphoma: report of two cases

Oncology research, 2002, Vol.13 (1), p.55

2002

Volltextzugriff (PDF)

Effects of docetaxel on the in vitro growth of human myeloid progenitors

Anticancer research, 1999-05, Vol.19 (3A), p.1855

1999

Volltextzugriff (PDF)

Advanced colorectal cancer: quality of life and toxicity in patients after weekly 24-hour continuous infusions of biomodulated 5-fluorouracil

Anticancer research, 2000-01, Vol.20 (1B), p.501

2000

Volltextzugriff (PDF)

In vitro toxicity of taxol based anticancer drug combinations on human hemopoietic progenitors

Anticancer research, 1999-01, Vol.19 (1A), p.409

1999

Volltextzugriff (PDF)

Toxicity on human hemopoietic progenitors of 2'-2'-difluoro-2'deoxycytidine (gemcitabine)

Anticancer research, 1998-03, Vol.18 (2A), p.1037

1998

Volltextzugriff (PDF)

In vitro toxicity of A 3'-azido-3'-deoxythymidine and hydroxyurea combination on normal myeloid progenitors

Anticancer research, 1998-07, Vol.18 (4A), p.2755

1998

Volltextzugriff (PDF)

Feasibility and toxicity of combination chemotherapy with ifosfamide, vinorelbine, cisplatin versus ifosfamide, vinorelbine in patients with advanced non small cell lung cancer

Anticancer research, 1997-07, Vol.17 (4A), p.2795

1997

Volltextzugriff (PDF)

Cisplatin inhibits erythroid committed progenitor (BFU-E) mobilization in peripheral blood

European journal of haematology, 1998-07, Vol.61 (1), p.65-70

1998

Volltextzugriff (PDF)

Interferon-alpha inhibits CFU-GM mobilization following chemotherapy and G-CSF administration

Journal of interferon & cytokine research, 1996-11, Vol.16 (11), p.953-956

1996

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(14)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cardiovascular disease (CVD) markers in patients(pts) with prostate cancer(PCa) treated with GN-RH agonists(AG) or antagonist(AN): a prospective cohort study

Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes

Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature

301 IRON OVERLOAD AND IRON CHELATION THERAPY WITH DEFERASIROX IN TRANSFUSION-DEPENDENT PATIENTS WITH MYELODYSPLASTIC SYNDROMES

202 BOTH AGE AND COMORBIDITIES NEGATIVELY IMPACT ON CLINICAL OUTCOME OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES: RESULTS FROM A REAL-LIFE REGIONAL SURVEY

P-158 Real-life current management of patients with myelodysplastic syndromes: A survey from a regional registry in north-western Italy

P-294 Azacytidine therapy for MDS and AML patients: Retrospective multicentre regional experience in patients not enrolled into clinical trials

P-140 Combined overexpression of WT1 and BAALC may predict evolution in MDS

1581P Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors (ICIs): Pooled analysis of individual cases from multiple institutions and literature

379 Serum hepcidin in patients with myelodysplastic syndrome and primary myelofibrosis

Dexamethazone-induced Acute Tumor Lysis Syndrome in a T-cell Malignant Lymphoma

Effects of retinoic acid and amifostine on in vitro growth of normal hemopoietic progenitor cells

Thalidomide-induced cardiotoxicity in multiple myeloma patients: An underestimated but clinically relevant issue

In vitro synergistic inhibition of human bone marrow hemopoietic progenitor growth by a 3'-azido-3'-deoxy-thymidine, 2',3'-dideoxycytidine combination

Amifostine promotes hemopoietic progenitor cell mobilization in patients with myelodysplastic syndrome

Epithelioid granulomas as main clinical manifestation at the outset of non-Hodgkin's lymphoma: report of two cases

Effects of docetaxel on the in vitro growth of human myeloid progenitors

Advanced colorectal cancer: quality of life and toxicity in patients after weekly 24-hour continuous infusions of biomodulated 5-fluorouracil

In vitro toxicity of taxol based anticancer drug combinations on human hemopoietic progenitors

Toxicity on human hemopoietic progenitors of 2'-2'-difluoro-2'deoxycytidine (gemcitabine)

In vitro toxicity of A 3'-azido-3'-deoxythymidine and hydroxyurea combination on normal myeloid progenitors

Feasibility and toxicity of combination chemotherapy with ifosfamide, vinorelbine, cisplatin versus ifosfamide, vinorelbine in patients with advanced non small cell lung cancer

Cisplatin inhibits erythroid committed progenitor (BFU-E) mobilization in peripheral blood

Interferon-alpha inhibits CFU-GM mobilization following chemotherapy and G-CSF administration

Suchergebnisse filtern